Thomas P Conrads

Sep 13, 2024 | nature.com | Laura Johnston |Allison Hunt |Thomas P Conrads |Mary Luu

AbstractRecent trials have shown the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-negative patients, but there is not yet a way to identify which patients will best respond, especially with the inability of current HER2 IHC and FISH assays to accurately determine HER2 expression in the unamplified setting.

May 5, 2024 | nature.com | Nicholas W Bateman |Tamara Abulez |Dale W. Garsed |Pang-ning Teng |Clifton L. Dalgard |Mariaelena Pierobon | +5 more

Correction to: npj Precision Oncology https://doi.org/10.1038/s41698-024-00519-8, published online 13 March 2024In the original version of this article, the wrong file was inadvertently supplied for Supplementary Data 15. The original article has been corrected.

Mar 12, 2024 | nature.com | Nicholas W Bateman |Tamara Abulez |Dale W. Garsed |Pang-ning Teng |Clifton L. Dalgard |Mariaelena Pierobon | +5 more

AbstractWe performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity.

Dec 1, 2023 | nature.com | John McGee |Pei Su |Nicholas W Bateman |Thomas P Conrads |Jeannie M. Camarillo |Jared O. Kafader

Correction to: Nature Communications https://doi.org/10.1038/s41467-023-42208-3, published online 14 October 2023The original version of the Article contained the following errors in Fig. 2: the proteoform signature ‘7125 Da’ was incorrectly labelled as ‘PSMD1’ in panels b and c; the labels ‘237 tumor pixels’ and ‘235 stroma pixels’ were incorrectly added to panel d and they have been removed in the correct version. The correct version of Fig.

Nov 3, 2023 | nature.com | Katherine Foster |Nicholas W Bateman |Kathleen Darcy |Thomas P Conrads |Philip L. Lorenzi

AbstractIn this study, we investigated the metabolic alterations associated with clinical response to chemotherapy in patients with ovarian cancer. Pre- and post-neoadjuvant chemotherapy (NACT) tissues from patients with high-grade serous ovarian cancer (HGSC) who had poor response (PR) or excellent response (ER) to NACT were examined.